Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Saudi J Biol Sci 24:14101417
Code Description Notes G9919-TH Positive comprehensive risk screening and provision of recommendations/referrals (Screening only positive if there is a DX code associated with the non-clinical risk factor indicated) At least one non-clinical risk factor Z-code should be included when billing G9919-TH G9920-TH Negative comprehensive risk screening (No non-clinical risk factor DX code reported) No risk factor Z-codes should be submitted when billing G9920-TH Prenatal screenings require a Gestational Age DX code
2) Develop standardized, clinically applicable biomarkers: Establish a multi-tiered biomarker panel combining biofluid-based markers (e.g., plasma oxPCs and urinary ferroptosis-related miRNAs) and tissue-based spatial signatures (e.g., ACSL4/GPX4 expression ratio in PT cells)
Some people experience a small drop in eGFR in the first few weeks of treatment
